A Phase 3 interventional study of CNTX-4975-05 and Placebo in Osteoarthritis, Knee, sponsored by Centrexion Therapeutics. Completed at 33 sites in United States. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-07-26.
Sponsored by Centrexion Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 100th largest by enrollment of the 691 interventional ones that give a count, is one of 55 that started in 2018, is one of 76 in phase 3, and was the 387th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
VA Office of Research and Development · Sites in United States
Ages 45–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 55 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 565 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
Centrexion Therapeutics is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Centrexion Therapeutics has 6 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo of 2.0 mL for IA injection
Drug: Placebo
Pre-filled glass syringes administered as a single 2.0 mL IA injection
Drug: CNTX-4975-05
Receiving CNTX-4975-05 injection
Receiving Placebo injection
Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee
Average daily OA pain in the index knee while walking was evaluated using a 0 to 10 Numerical Pain Rating Scale (NPRS) (0 = no pain and 10 = worst possible pain). 0 was the best score and 10 was the worst score. Subjects used an ePRO at bedtime (9:00 PM ± 3 hours) to record on a daily basis their average daily OA knee pain score with walking during the previous 24 hours.
Time frame: Baseline, Week 12
Mean Change From Baseline in WOMAC A (Pain) Dimension Total Score
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The pain dimension includes 5 items about the amount of pain experienced doing various activities (walking, stair climbing, nocturnal, at rest, weight bearing). The score ranges from 0 to 50.
Time frame: Baseline, Week 12
Mean Change From Baseline WOMAC B (Stiffness) Dimension Total Score
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The stiffness dimension has 2 items: joint stiffness upon wakening and joint stiffness later in the day. The score ranges from 0 to 20.
Time frame: Baseline, Week 12
Mean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The function dimension asks about the degree of difficulty in doing 17 activities due to the reference joint. The score ranges from 0 to 170.
Time frame: Baseline, Week 12
| Milestone | Placebo | CNTX-4975-05 |
|---|---|---|
| Started | 138 | 194 |
| Treated | 136 | 189 |
| Completed | 110 | 152 |
| Not completed | 28 | 42 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Lost to follow-up | 9 | 8 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Sponsor decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 20 |
| Withdrew: Other reasons: unable to administer ip, collect aspirate | 3 | 8 |
Average daily OA pain in the index knee while walking was evaluated using a 0 to 10 Numerical Pain Rating Scale (NPRS) (0 = no pain and 10 = worst possible pain). 0 was the best score and 10 was the worst score. Subjects used an ePRO at bedtime (9:00 PM ± 3 hours) to record on a daily basis their average daily OA knee pain score with walking during the previous 24 hours.
| score on a scale | Placebo | CNTX-4975-05 |
|---|---|---|
| Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee | -2.84 ± 0.212 | -3.17 ± 0.182 |
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The pain dimension includes 5 items about the amount of pain experienced doing various activities (walking, stair climbing, nocturnal, at rest, weight bearing). The score ranges from 0 to 50.
| score on a scale | Placebo | CNTX-4975-05 |
|---|---|---|
| Mean Change From Baseline in WOMAC A (Pain) Dimension Total Score | -12.72 ± 1.002 | -15.42 ± 0.860 |
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The stiffness dimension has 2 items: joint stiffness upon wakening and joint stiffness later in the day. The score ranges from 0 to 20.
| score on a scale | Placebo | CNTX-4975-05 |
|---|---|---|
| Mean Change From Baseline WOMAC B (Stiffness) Dimension Total Score | -5.21 ± 0.448 | -6.15 ± 0.386 |
The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index that contains 24 items asked in relation to the index knee joint. The WOMAC has 3 dimensions: Pain (Subscale A), Stiffness (Subscale B), and Physical Function (Subscale C). Lower scores mean a better outcome and higher scores mean a worse outcome. The function dimension asks about the degree of difficulty in doing 17 activities due to the reference joint. The score ranges from 0 to 170.
| score on a scale | Placebo | CNTX-4975-05 |
|---|---|---|
| Mean Change From Baseline in WOMAC C (Physical Function) Dimension Total Score | -42.70 ± 3.417 | -50.49 ± 2.935 |
Collected over 1 Year. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/136 (0%) | 6/136 (4.4%) | 45/136 (33.1%) |
| CNTX-4975-05 | 1/189 (0.5%) | 6/189 (3.2%) | 110/189 (58.2%) |
| Event | Placebo | CNTX-4975-05 |
|---|---|---|
| Foot FractureInjury, poisoning and procedural complications | 1/136 | 0/189 |
| Hip FractureInjury, poisoning and procedural complications | 1/136 | 0/189 |
| Chest PainGeneral disorders | 1/136 | 0/189 |
| Oestrogen receipt positive breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/136 | 0/189 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/136 | 0/189 |
| Peripheral IschaemiaVascular disorders | 1/136 | 0/189 |
| Vertigo PositionalEar and labyrinth disorders | 1/136 | 0/189 |
| Hip ArthroplastySurgical and medical procedures | 1/136 | 0/189 |
| Acetabulum FractureInjury, poisoning and procedural complications | 0/136 | 1/189 |
| Craniocerebral InjuryInjury, poisoning and procedural complications | 0/136 | 1/189 |
| Event | Placebo | CNTX-4975-05 |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/136 | 19/189 |
| NauseaGastrointestinal disorders | 2/136 | 12/189 |
| Upper respiratory tract infectionInfections and infestations | 7/136 | 8/189 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/136 | 8/189 |
| DizzinessNervous system disorders | 3/136 | 6/189 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/136 | 6/189 |
| Back painMusculoskeletal and connective tissue disorders | 2/136 | 5/189 |
| Joint effusionMusculoskeletal and connective tissue disorders | 1/136 | 5/189 |
| InfluenzaInfections and infestations | 1/136 | 5/189 |
| Procedural painInjury, poisoning and procedural complications | 2/136 | 5/189 |
The safety population is defined as any subject that received any amount of investigational product
| Age, Continuous(Years) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Mean | 61.8 ± 9.5 | 61.8 ± 9.1 | 61.8 ± 9.2 |
| Sex: Female, Male(Participants) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Female | 83 | 123 | 206 |
| Male | 53 | 66 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 37 | 60 |
| Not Hispanic or Latino | 113 | 152 | 265 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 12 | 15 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 30 | 46 | 76 |
| White | 90 | 123 | 213 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Body Mass Index(kg/m^2) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Mean | 32.07 ± 5.801 | 31.55 ± 5.692 | 31.77 ± 5.734 |
| Baseline Pain with Walking NPRS (0-10) Score(score on a scale) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Mean | 7.09 ± 1.152 | 7.06 ± 1.082 | 7.07 ± 1.110 |
| Baseline WOMAC A (Pain) Domain Score (range 0-50)(score on a scale) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Mean | 30.80 ± 8.166 | 31.92 ± 7.493 | 31.45 ± 7.788 |
| Baseline WOMAC B (Stiffness) Domain Score (range 0-20)(score on a scale) | Placebo | CNTX-4975-05 | Total |
|---|---|---|---|
| Mean | 13.24 ± 3.389 | 13.28 ± 3.232 | 13.26 ± 3.293 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Nov 2019, 21 months.
Results were first posted in Apr 2022, 2 years 4 months after primary completion.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 21 months is close to that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CNTX-4975-05
Centrexion Therapeutics